letrozole,palbociclib
pfizer,novartis
['paloma-2']
#asco2022 finn paloma-2 final os analysis of 1st-line palbo plus letrozole vs pla plus let. lots of missing data. median os 54 vs 51.2 mo, ns. excluding missing patients results in somewhat better looking data, but such analyses are suspicious.
Professor of Medicine, Stanford University; breast cancer doc